Updated:
Natera
Matthew Rabinowitz founded Natera in 2004. The firm has processed over 16 million cell-free DNA tests and focuses on oncology, women's health, and organ...
Natera
Matthew Rabinowitz founded Natera in 2004. The firm emerged from a personal tragedy — his sister's son died six days after birth from a severe genetic condition. Rabinowitz started Natera to increase access to early detection of genetic disease through cell-free DNA testing. Natera focuses on three clinical areas: oncology, women's health, and organ health. Its oncology tests use the Signatera™ tumor-informed circulating tumor DNA assay to characterize tumors and detect recurrence. The Panorama™ noninvasive prenatal test and Prospera™ donor-derived cfDNA assay target women's health and transplant monitoring respectively. The firm has participated in landmark prospective studies: the CIRCULATE trial for colorectal cancer (3,000+ patients), the SMART study for prenatal testing (18,000+ pregnancies), and the Trifecta cohort for kidney transplant recipients. Natera's geographic footprint includes labs and offices in San Carlos, California, and Austin, Texas, with over 400 peer-reviewed publications supporting its assays. Natera has processed over 16 million tests in its CLIA-certified, CAP-accredited laboratories. The firm employs more than 150 medical professionals who provide patient and provider support. Over 70,000 support sessions occur annually. A May 29, 2026 announcement revealed a collaboration with Diakonos Oncology to evaluate Signatera™ in refractory melanoma. On May 26, 2026, Natera announced the launch of an enhanced Panorama™ NIPT powered by novel SNP-informed deep sequencing technology. Unlike many molecular diagnostics firms, Natera has built its clinical evidence base through large, prospective studies across its three core areas. This trial-first approach creates a structural barrier for competitors and directly informs test adoption by health systems and insurers.
General information
Firm type
other
Year founded
2004
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Carlos
Corporate office
San Carlos, CA, United States
Additional offices
Austin, TX, United States
Principals
Matthew Rabinowitz
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Natera?
Natera is not an investment firm but a molecular diagnostics company. Investment decisions are made by the CEO and board, prioritizing clinical trial funding and commercial expansion. The firm does not manage third-party capital or operate as a family office.
Does Natera participate in fund commitments or only direct operations?
Natera is a diagnostics company, not a fund. It does not make fund commitments or direct investments as a limited partner. Its capital deployment is entirely operational—R&D, laboratory infrastructure, and commercial sales.
What clinical areas does Natera focus on?
Natera operates in three clinical areas: oncology (using the Signatera™ ctDNA test for molecular residual disease monitoring), women's health (Panorama™ noninvasive prenatal testing), and organ health (Prospera™ donor-derived cfDNA for transplant rejection monitoring). These are supported by a pipeline of large prospective studies.
How is Natera related to any family office?
Natera is a publicly traded company (NASDAQ: NTRA). It has no disclosed connection to any single-family or multi-family office. Founder Matthew Rabinowitz may have personal wealth structures, but those are not publicly linked to the firm's operations.
Where does the underlying wealth come from?
Natera is a public corporation. Its market capitalization is derived from public equity investors. Founder Matthew Rabinowitz's wealth originates from his equity stake in the company, but the firm itself does not disclose private wealth origins.
Does Natera maintain philanthropic structures, and how are they separated?
Natera’s website describes a sustainability program focused on reducing environmental impact in its labs, offices, and supply chain. The firm does not publicly disclose a separate philanthropic foundation. There is no evidence of a corporate foundation or donor-advised fund directly linked to the company.
What is Natera's known posture on co-investments alongside external GPs?
Natera does not co-invest with external general partners. The firm is a diagnostics business, not an investment vehicle. Its partnerships are clinical and commercial in nature—such as the May 2026 collaboration with Diakonos Oncology—and do not involve co-investment structures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: